Three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab based allogeneic stem cell transplants for haematological malignancies

Kanellopoulos, Alexandros; McIlroy, Graham; Paneesha, Shankara; Kaparou, Maria; Kishore, Bhuvan; Lovell, Richard; Elmoamly, Shereef; Davies, David; Xenou, Evgenia; Horgan, Claire; Kinsella, Francesca; Arbuthnot, Carolina; Borg, Anton; Randall, Katie; Ryann, Lynn; Collins, Katie; Holder, Kathleen; Pryor, Rebecca; Gudger, Amy; Giles, Hannah; Milligan, Donald; Nikolousis, Emmanouil

Affiliation

Heart of England NHS Foundation Trust; University of Birmingham; South Warwickshire University NHS Foundation Trust

Publication date

2018-11-19

Subject

Haematology
Transplantation

Metadata

Show full item record

Abstract

This European Society for Blood and Marrow Transplantation conference abstract reports that three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab based allogeneic stem cell transplants for haematological malignancies.

Citation

Kanellopoulos A, McIlroy G, Elmoamly DD, Xenou E, Horgan C, Kinsella F, Arbuthnot C, Borg A, Randall K, Ryann L, Collins K. Three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab-based allogeneic stem cell transplants for haematological malignancies. Bone Marrow Transplantation. 2018;53:295. doi: 10.1038/s41409-018-0354-7.

Type

Conference Output